DelveInsight Blog
Trending:
Pharma M&A Rebound May Take a While i...
Dec 22, 2016
The only word that described 2016’s pharma M&A market was “slow.” Some do predict that new year—and administratio...
How are Antipsychotics Transforming the Sc...
Sep 30, 2022
Schizophrenia affects approximately 24 million people worldwide, or 1 in every 300 people (0.32%). In adults, this ra...
Asahi Intecc Partners with Penumbra; Proso...
Sep 29, 2022
Asahi Intecc partners with Penumbra to roll out Indigo System in Japan On September 22, 2022, Asahi Intecc, a Surgica...
Sign Up and Stay Informed
Penetrative insights and rich analysis of Pharma, Biotech and MedTech space.
Editor's Pick
Which Pipeline Therapy Has The Potential To Revolutionize The Dystrophic Epid...
Dystrophic epidermolysis bullosa (DEB) is a common skin disease with a chronic history ...
Can FcRn Antagonists Be The Game-Changer in the Generalized Myasthenia Gravis...
Though a rare disease, generalized myasthenia gravis (gMG) still affects around 60,000 ...
Exploring Potential New Avenues for Bronchopulmonary Dysplasia Treatment
Bronchopulmonary Dysplasia is the most common long-term respiratory morbidity of low-we...
A Market Space Beyond Lucentis and Eylea for Retinal Vein Occlusion Treatment
Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landsc...
NexoBrid and its Awaiting US Approval
A Burn takes place when the skin comes into contact with a heat source. Burns can occur...
RECENT ARTICLES
-Agonist.png "Toll-like Receptors Agonist")
